Search for Articles:
Title / Keyword
Author / Affiliation / Email
Journal
Article Type
 
 
Advanced Search
 
Section
Special Issue
Volume
Issue
Number
Page
 
5.4
3.9
Journals
JCM
Special Issues
Progress in Hematopoietic Stem Cell Transplantation and Cellular Therapies
share announcement

Progress in Hematopoietic Stem Cell Transplantation and Cellular Therapies

A special issue of Journal of Clinical Medicine (ISSN 2077-0383). This special issue belongs to the section "Hematology".

Deadline for manuscript submissions: closed (20 June 2022) | Viewed by 15120

Special Issue Editors

Dr. Ciprian Tomuleasa

E-Mail Website
Guest Editor
Ion Chiricuta Clinical Cancer Center, 400012 Cluj-Napoca, Romania
Interests: hematological malignancies; hematopoiesis; stem cell transplantation; immunotherapy
Special Issues, Collections and Topics in MDPI journals
Dr. Alina Tanase

E-Mail Website
Guest Editor
Fundeni Clinical Institute, Bucharest, Romania
Interests: bench-to-medside; experimental therapeutics; stem cell transplantation
Special Issues, Collections and Topics in MDPI journals
Dr. Anca Colita

E-Mail Website
Guest Editor
Fundeni Clinical Institute, Carol Davila University of Medicine and Pharmacy, Bucharest, Romania
Interests: acute leukemias; stem cell transplanation; CAR-T therapy
Special Issues, Collections and Topics in MDPI journals

Special Issue Information

Dear Colleagues,

Hematological malignancies are considered to be one of the most important causes of mortality and morbidity in the modern world. Still, important progress has been made in the last decade due to breakthroughs in hematopoietic stem cell transplantation and cellular therapies. The results of recent studies show that a promising road toward state-of-the-art treatment for the hematology patient, turning the diagnosis of leukemia or lymphoma into a curable disease, has already begun, with recent advances in hematopoietic stem cell transplantation and immunotherapy, and is now progressing forward. The prospect of providing a definitive alternative therapy for various malignancies, rather than conventional chemotherapy management, is indeed clinically, socially, and economically attractive, due to the huge medical, social, and economic burden that a malignancy imposes. The current joint Special Issue aims to present a modern approach in the recent advances in stem cell transplantation for the hematological patient, with a special emphasis on progress in conditioning chemotherapy and cellular therapies.

The present call for manuscripts addresses healthcare professionals that diagnose, treat, and research stem cell transplantation, with a special emphasis on state-of-the-art therapeutics and novel, emerging drugs and novel cellular therapies. Comprehensive reviews original research (may it be basic, or clinical research), or even interesting case series are welcomed, with the goal of presenting new approaches in the clinical management of patients, patients diagnosed with a malignancy and undergoing stem cell transplantation, as well as approaches that may be newly approved drugs, clinical trials in the pipeline, or even promising future therapeutic alternatives.

Dr. Ciprian Tomuleasa
Dr. Alina Tanase
Dr. Anca Colita
Guest Editors

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Journal of Clinical Medicine is an international peer-reviewed open access semimonthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2600 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.

Keywords

  • experimental therapeutics
  • translational medicine
  • epigenetics
  • preclinical data
  • cancer

Related Special Issue

Published Papers (6 papers)

Download All Papers
Order results
Result details
Show export options expand_more Show export options expand_less
Select all
Export citation of selected articles as:

Editorial

Jump to: Research, Review

3 pages, 202 KiB  
Editorial
Progress in Hematopoietic Stem Cell Transplantation and Cellular Therapies
by Diana Cenariu, Horia Bumbea, Anca Colita, Catalin Constantinescu, Minodora Desmirean, Sabina Iluta, Daniel Lysák, Alberto Mussetti, Ioana Tichil, Alina Tanase and Ciprian Tomuleasa
J. Clin. Med. 2022, 11(24), 7354; https://doi.org/10.3390/jcm11247354 - 10 Dec 2022
Viewed by 1053
Abstract
Hematological malignancies are considered to be one of the most important causes of mortality and morbidity in the modern world [...] Full article
(This article belongs to the Special Issue Progress in Hematopoietic Stem Cell Transplantation and Cellular Therapies)

Research

Jump to: Editorial, Review

14 pages, 1262 KiB  
Article
Platelet Defects in Acute Myeloid Leukemia—Potential for Hemorrhagic Events
by Horia Bumbea, Ana Maria Vladareanu, Ion Dumitru, Viola Maria Popov, Cristina Ciufu, Anca Nicolescu, Minodora Onisai, Cristina Marinescu, Diana Cisleanu, Irina Voican and Sinziana Sarghi
J. Clin. Med. 2022, 11(1), 118; https://doi.org/10.3390/jcm11010118 - 26 Dec 2021
Cited by 8 | Viewed by 3270
Abstract
Background and objectives: In acute myeloid leukemia (AML), extensive bleeding is one of the most frequent causes of death. Impaired activation and aggregation processes were identified in previous studies on platelet behaviour associated with this disease. This study’s aim was to examine platelet [...] Read more.
Background and objectives: In acute myeloid leukemia (AML), extensive bleeding is one of the most frequent causes of death. Impaired activation and aggregation processes were identified in previous studies on platelet behaviour associated with this disease. This study’s aim was to examine platelet function in correlation with other haemorrhage risk factors (fever, sepsis, recent bleeding, uraemia, leucocytosis, haematocrit value, treatment). Design and methods: The analysis of platelet surface proteins (Glycoprotein Ib-IX (CD42b, CD42a), Glycoprotein IIb-IIIa (CD41, CD61), p-selectin (CD62P), granulophysin (CD63)) was conducted by flowcytometry from samples of whole blood in patients with acute myeloid leukaemia in different stages of diagnosis and therapy (n = 22) in comparison with healthy human controls (n = 10). Results and interpretations: Our results show a significant decrease in fluorescence level associated with platelet activation markers (CD63 (14.11% vs. 40.78 % p < 0.05); CD62P (15.26% vs. 28.23% p < 0.05)); adhesion markers (CD42b (69.08% vs. 84.41% p < 0.05)) and aggregation markers (CD61 (83.79% vs. 98.62% p < 0.001)) in patients compared to controls. The levels of CD41 (80.62% vs. 86.31%, p = 0.290) and CD42a (77.98% vs. 94.15%, p = 0.99) demonstrate no significant differences in the two groups. Conclusion: The AML patients present changes in adhesion receptors and activation markers, suggesting a functional defect or denatured intracellular signalling in platelets. The exposed data indicate that flow cytometry can effectively identify multiple functional platelet impairments in AML pathogenesis. Full article
(This article belongs to the Special Issue Progress in Hematopoietic Stem Cell Transplantation and Cellular Therapies)
►▼ Show Figures

Figure 1

8 pages, 1217 KiB  
Article
Should We Stop Collecting the Preoperative Autologous Blood before Bone Marrow Harvest?
by Daniel Lysák, Lenka Hejretová, Marcela Hrabětová and Pavel Jindra
J. Clin. Med. 2021, 10(10), 2134; https://doi.org/10.3390/jcm10102134 - 14 May 2021
Cited by 5 | Viewed by 1802
Abstract
Preoperative autologous blood donation (PAD) in bone marrow (BM) donors is performed to meet potential post-harvest transfusion needs and to avoid the risk of allogeneic transfusions. We reviewed retrospectively bone marrow harvests in 216 healthy donors during a ten-year period to determine the [...] Read more.
Preoperative autologous blood donation (PAD) in bone marrow (BM) donors is performed to meet potential post-harvest transfusion needs and to avoid the risk of allogeneic transfusions. We reviewed retrospectively bone marrow harvests in 216 healthy donors during a ten-year period to determine the use of autologous blood. All donors except four had undergone PAD. The initial hemoglobin level of 153 g/L (male donors) and 135 g/L (female donors), respectively, decreased by about 8 g/L after preoperative blood donation and by 23 g/L after bone marrow harvest (medians). Autologous blood was administered to 70% of donors, 30% of the units remained unused. The evaluation of the risk of reaching transfusion threshold (<115 g/L males, <105 g/L females) revealed that donors with initial hemoglobin above 145 g/L and those weighing above 75 kg have minimal risk of requiring blood substitution (about 10%). A larger volume of bone marrow was obtained from male compared to female donors (1300 vs. 1100 mL) because of their higher body weight, which resulted in a higher number of procured nucleated cells (362 vs. 307 × 106/kg TNC, ns). The donor-recipient weight difference predicted the probability of sufficient collection. Only 1.5% of donors weighing ≥ 20 kg more than recipients failed to reach ≥3 × 108/kg TNC recipient. Our findings affirm previous data that PAD is unnecessary for healthy marrow donors and may be indicated individually after considering the pre-collection hemoglobin level, donor and recipient weight, and expected blood loss. Reasonable substitution cut-offs have to be set together with clinical symptom evaluation. The effective use of PAD also requires an adequate time interval between PAD and BM harvest. Full article
(This article belongs to the Special Issue Progress in Hematopoietic Stem Cell Transplantation and Cellular Therapies)
►▼ Show Figures

Figure 1

9 pages, 950 KiB  
Article
Treatment of Anaemia in Patients with Acute Burn Injury: A Study of Blood Transfusion Practices
by Ioana Tichil, Samara Rosenblum, Eldho Paul and Heather Cleland
J. Clin. Med. 2021, 10(3), 476; https://doi.org/10.3390/jcm10030476 - 27 Jan 2021
Cited by 8 | Viewed by 2976
Abstract
Objective: To determine blood transfusion practices, risk factors, and outcomes associated with the use of blood products in the setting of the acute management of burn patients at the Victorian Adult Burn Service. Background: Patients with burn injuries have variable transfusion [...] Read more.
Objective: To determine blood transfusion practices, risk factors, and outcomes associated with the use of blood products in the setting of the acute management of burn patients at the Victorian Adult Burn Service. Background: Patients with burn injuries have variable transfusion requirements, based on a multitude of factors. We reviewed all acute admissions to the Victorian Adult Burns Service (VABS) between 2011 and 2017: 1636 patients in total, of whom 948 had surgery and were the focus of our analysis. Method and results: Patient demographics, surgical management, transfusion details, and outcome parameters were collected and analyzed. A total of 175 patients out of the 948 who had surgery also had a blood transfusion, while 52% of transfusions occurred in the perioperative period. The median trigger haemoglobin in perioperative was 80mg/dL (IQR = 76–84.9 mg/dL), and in the non-perioperative setting was 77 mg/dL (IQR = 71.61–80.84 mg/dL). Age, gender, % total body surface area (TBSA) burn, number of surgeries, and intensive care unit and hospital length of stay were associated with transfusion. Conclusions: The use of blood transfusions is an essential component of the surgical management of major burns. As observed in our study, half of these transfusions are related to surgical procedures and may be influenced by the employment of blood conserving strategies. Furthermore, transfusion trigger levels in stable patients may be amenable to review and reduction. Risk adjusted analysis can support the implementation of blood transfusion as a useful quality indicator in burn care. Full article
(This article belongs to the Special Issue Progress in Hematopoietic Stem Cell Transplantation and Cellular Therapies)
►▼ Show Figures

Figure 1

Review

Jump to: Editorial, Research

15 pages, 269 KiB  
Review
Is Post-Transplant Cyclophosphamide the New Methotrexate?
by Alberto Mussetti, Annalisa Paviglianiti, Rocio Parody and Anna Sureda
J. Clin. Med. 2021, 10(16), 3548; https://doi.org/10.3390/jcm10163548 - 12 Aug 2021
Cited by 10 | Viewed by 2188
Abstract
Introducing post-transplant, cyclophosphamide (PT-Cy) graft-versus-host disease (GVHD) prophylaxis in the setting of haploidentical donor transplantation has marked the most important advance in allogeneic hematopoietic cell transplantation (alloHCT) within the past 15 years. The efficacy of this procedure and its simple features have allowed [...] Read more.
Introducing post-transplant, cyclophosphamide (PT-Cy) graft-versus-host disease (GVHD) prophylaxis in the setting of haploidentical donor transplantation has marked the most important advance in allogeneic hematopoietic cell transplantation (alloHCT) within the past 15 years. The efficacy of this procedure and its simple features have allowed for the significantly widespread application of alloHCT worldwide. Indeed, the procedure’s effectiveness in reducing immunological complications in the haploidentical setting has even challenged the status quo use of calcineurin-inhibitor, methotrexate-based GVHD prophylaxis in the setting of HLA-identical donors. Currently, however, prospective clinical trials in support of PT-Cy-based GVHD prophylaxis in the HLA-matched setting are striving to resolve the matter of its potential role. This review will briefly report the overall outcomes of PT-Cy-based GVHD prophylaxis in the haploidentical setting and summarize results obtained in the HLA-identical field. We will present future perspectives at the end of the manuscript. Full article
(This article belongs to the Special Issue Progress in Hematopoietic Stem Cell Transplantation and Cellular Therapies)
23 pages, 1055 KiB  
Review
B Cells versus T Cells in the Tumor Microenvironment of Malignant Lymphomas. Are the Lymphocytes Playing the Roles of Muhammad Ali versus George Foreman in Zaire 1974?
by Minodora Desmirean, Sebastian Rauch, Ancuta Jurj, Sergiu Pasca, Sabina Iluta, Patric Teodorescu, Cristian Berce, Alina-Andreea Zimta, Cristina Turcas, Adrian-Bogdan Tigu, Cristian Moldovan, Irene Paris, Jakob Steinheber, Cedric Richlitzki, Catalin Constantinescu, Olafur Eysteinn Sigurjonsson, Delia Dima, Bobe Petrushev and Ciprian Tomuleasa
J. Clin. Med. 2020, 9(11), 3412; https://doi.org/10.3390/jcm9113412 - 24 Oct 2020
Cited by 2 | Viewed by 2644
Abstract
Malignant lymphomas are a heterogeneous group of malignancies that develop both in nodal and extranodal sites. The different tissues involved and the highly variable clinicopathological characteristics are linked to the association between the lymphoid neoplastic cells and the tissues they infiltrate. The immune [...] Read more.
Malignant lymphomas are a heterogeneous group of malignancies that develop both in nodal and extranodal sites. The different tissues involved and the highly variable clinicopathological characteristics are linked to the association between the lymphoid neoplastic cells and the tissues they infiltrate. The immune system has developed mechanisms to protect the normal tissue from malignant growth. In this review, we aim to explain how T lymphocyte-driven control is linked to tumor development and describe the tumor-suppressive components of the resistant framework. This manuscript brings forward a new insight with regard to intercellular and intracellular signaling, the immune microenvironment, the impact of therapy, and its predictive implications. A better understanding of the key components of the lymphoma environment is important to properly assess the role of both B and T lymphocytes, as well as their interplay, just as two legendary boxers face each other in a heavyweight title final, as was the case of Ali versus Foreman. Full article
(This article belongs to the Special Issue Progress in Hematopoietic Stem Cell Transplantation and Cellular Therapies)
►▼ Show Figures

Figure 1

Show export options expand_more Show export options expand_less
Select all
Export citation of selected articles as:
 
Displaying articles 1-6
Back to TopTop